The Analysis Of Relationship Between HER2 Expression And Clinicopathological Features And Prognosis Of Luminal Type Breast Cancer

Purpose: To analyze the association between the HER2 status and the clinicopathological features and the risk of recurrence and metastasis of patients with type Luminal breast cancer after adjuvant endocrine therapy.Methods: Clinical data of 723 breast cancer patients who received standard resection ± adjuvant chemotherapy ± adjuvant radiotherapy and endocrine therapy in the Affiliated Tumor Hospital of Guangxi Medical University from January 2009 to December 2013 were retrospectively collected in our study.We analyzed the relationship between different HER2 status and the clinical and pathological features and the efficacy of adjuvant endocrine therapy were analyzed by chi-square test,log-rank test,Cox proportional hazards regression model,respectively.Results: A total of 723 patients were included in the analysis,202 of 726 patients were identified to be HER2-positive.HER2-positivity was markedlyassociated with larger tumour size,higher Ki-67 and lower ER and PR expression.Patients with HER2-positive tumours were treated more frequently with chemotherapy.At a median follow-up of 40.4 months,a total of 109 patients were recorded local recurrence or metastasis,and there was no significant difference in local recurrence and distant metastasis between the HER2-positive and HER2-negative patients.There were significant differences in the incidence of primary endocrine resistance and secondary resistance between HER2-positive and HER2-negative,with HER2-positive is prone to primary endocrine resistance.DFS was poorer in patients with HER2-positive than in those with HER2-negative(HR=1.522;95%CI [0.998,2.345];P=0.036).HER2-positive patients showed a poor DFS in both hormone receptor status and endocrine drugs-treated patients,but the difference was not statistically significant.Multivariate analysis showed that lymph node and Ki-67 were independent prognostic factors of DFS in patients with hormone receptor positive breast cancer.Conclusion:HER2-positivity was associated with larger tumour size,higher Ki-67 and lower ER and PR expression.Compared with HER2-negative breast cancer,endocrine therapy for HER2-positive breast cancer is prone to primary endocrine resistance and have an increased risk of recurrence.